Reata Pharmaceuticals, Inc. ("Reata") today announced interim results from its ongoing Phase 1 trial of RTA 744 in advanced primary brain tumors. These results were presented at the annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics held this week in Prague, Czech Republic. [click link for full article]
More...